Donanemab in Early Symptomatic Alzheimer's (TRAILBLAZER-ALZ 2)
Phase 3 CompletedEarly Symptomatic Alzheimer's Disease
Target intervention
Donanemab (anti-N3pG amyloid)
Primary endpoint
Integrated AD Rating Scale (iADRS) at 76 weeks
Summary
35% slowing on iADRS in low/medium tau population; 2nd FDA-approved disease-modifier (Kisunla, July 2024).
Protocol timeline
Phase I
Phase II
Phase III
Phase IV
Current status Completed
Enrolled n = 1,736